Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.

PubWeight™: 5.42‹?› | Rank: Top 1%

🔗 View Article (PMID 8037405)

Published in Ann Intern Med on August 15, 1994

Authors

E Giovannucci1, E B Rimm, M J Stampfer, G A Colditz, A Ascherio, W C Willett

Author Affiliations

1: Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.

Associated clinical trials:

Health Professionals Follow-up Study | NCT00005182

Articles citing this

(truncated to the top 100)

Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol (2016) 4.90

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84

Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03

Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88

The causes and prevention of cancer. Proc Natl Acad Sci U S A (1995) 3.71

Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ (2000) 3.10

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99

Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73

Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88

Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer (1999) 1.85

Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest (1995) 1.81

Type 2 diabetes and the risk of colorectal adenomas: Black Women's Health Study. Am J Epidemiol (2013) 1.72

Targeting the tumor microenvironment. Front Biosci (2007) 1.72

Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63

Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A (1998) 1.62

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62

Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut (1999) 1.59

Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res (2012) 1.58

Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest (1997) 1.54

Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer (2012) 1.54

Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology (2011) 1.44

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut (1996) 1.42

Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol (2011) 1.34

Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer (2000) 1.31

Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA (2012) 1.29

Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest (1996) 1.27

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer (1999) 1.25

Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol (1999) 1.24

Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut (2010) 1.20

Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19

Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci (1998) 1.15

Metabolic syndrome and gastrointestinal diseases. J Gastroenterol (2007) 1.12

Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer (2004) 1.10

Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08

Effects of sulindac on sporadic colorectal adenomatous polyps. Gut (1997) 1.07

Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07

Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut (1996) 1.06

The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones (2008) 1.04

COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02

Estimating the heritability of colorectal cancer. Hum Mol Genet (2014) 1.02

Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women. Genes Chromosomes Cancer (2011) 0.99

A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia (2001) 0.99

Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer (2011) 0.98

Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett (2008) 0.97

Myofibroblasts: paracrine cells important in health and disease. Trans Am Clin Climatol Assoc (2000) 0.97

Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer (2011) 0.96

Genome-wide diet-gene interaction analyses for risk of colorectal cancer. PLoS Genet (2014) 0.96

Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci (2001) 0.96

Aspirin use and lung cancer in men. Br J Cancer (2003) 0.95

Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br J Cancer (1999) 0.95

Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia (2012) 0.95

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer (2001) 0.95

COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut (2000) 0.94

Aspirin and colorectal cancer. Br J Cancer (1997) 0.94

Aspirin for primary prevention of cardiovascular events. J Gen Intern Med (1998) 0.94

Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer (2008) 0.93

Prevalence and distribution of adenomas in black Americans undergoing colorectal cancer screening. Dig Dis Sci (2011) 0.91

Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med (2010) 0.91

Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Invest (1996) 0.90

Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics (2007) 0.90

Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia (1999) 0.90

Perils of immunohistochemistry: variability in staining specificity of commercially available COX-2 antibodies on human colon tissue. Dig Dis Sci (2003) 0.89

Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig Dis Sci (1998) 0.89

Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut (2003) 0.89

Chemoprevention of colorectal cancer. Gut (1998) 0.88

Comparative efficacy of 5flourouracil/calcium leucovorine versus 5flourouracil/calcium leucovorine plus oxaliplatin in the adjuvant treatment of colonic carcinoma in Kashmir. South Asian J Cancer (2013) 0.88

A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One (2010) 0.88

Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study. Cancer Prev Res (Phila) (2013) 0.87

Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals. Am J Epidemiol (2011) 0.87

TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.87

White blood cell count and the risk of colon cancer. Yonsei Med J (2006) 0.87

Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol (2008) 0.86

Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. Biochem Pharmacol (2007) 0.86

COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer. Br J Cancer (2002) 0.86

Risk factors for self-reported colon polyps. J Gen Intern Med (1998) 0.85

Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis (2003) 0.85

Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prev Res (Phila) (2010) 0.83

Geranylgeranylacetone protects cultured guinea pig gastric mucosal cells from indomethacin. Dig Dis Sci (2000) 0.83

Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract (2012) 0.82

Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol (2012) 0.81

Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int J Colorectal Dis (2003) 0.81

Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci (2006) 0.80

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol (2014) 0.80

Strategies for colon cancer prevention. EPMA J (2010) 0.80

Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J (2005) 0.79

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer (2007) 0.78

Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women. Cancer Prev Res (Phila) (2015) 0.78

Two-dimensional polyacrylamide gel electrophoresis analysis of indomethacin-treated human colon cancer cells. World J Gastroenterol (2005) 0.78

Concept of chemoprevention in colorectal cancer. World J Gastrointest Oncol (2009) 0.78

NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect? J Gen Intern Med (2007) 0.77

Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Semin Intervent Radiol (2010) 0.77

Association of Nonsteroidal Anti-Inflammatory Drugs with Colorectal Cancer by Subgroups in the VITamins and Lifestyle (VITAL) Study. Cancer Epidemiol Biomarkers Prev (2015) 0.77

Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention. Med Chem Res (2014) 0.76

Familiar drugs may prevent cancer. Postgrad Med J (2001) 0.75

Are we making progress in diagnosing and preventing gastrointestinal cancers? Therap Adv Gastroenterol (2010) 0.75

Aspirin and colorectal cancer. Ann Intern Med (1995) 0.75

The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis. J Cancer (2016) 0.75

Articles by these authors

Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol (1985) 26.13

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85

Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol (1992) 17.17

Total energy intake: implications for epidemiologic analyses. Am J Epidemiol (1986) 16.34

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med (2001) 14.48

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08

Body weight and mortality among women. N Engl J Med (1995) 11.04

Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol (1989) 10.98

Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84

Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57

Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11

Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol (1994) 9.90

Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc (1993) 9.90

Aspirin and the risk of colorectal cancer in women. N Engl J Med (1995) 9.59

Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol (1999) 9.34

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28

Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med (2000) 9.05

Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med (1990) 8.98

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66

Prospective study of alcohol consumption and risk of coronary disease in men. Lancet (1991) 8.64

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60

Test of the National Death Index. Am J Epidemiol (1984) 8.46

Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43

Misinterpretation and misuse of the kappa statistic. Am J Epidemiol (1987) 8.29

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17

Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet (1991) 7.87

Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62

A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol (1990) 7.24

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care (1994) 7.11

Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA (1998) 7.09

Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med (2001) 7.07

Guidelines for healthy weight. N Engl J Med (1999) 7.03

Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr (1999) 7.02

Plasma organochlorine levels and the risk of breast cancer. N Engl J Med (1997) 7.02

Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA (1997) 6.92

A gender-specific measure of binge drinking among college students. Am J Public Health (1995) 6.79

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50

Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol (1994) 6.47

The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med (2001) 6.37

Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37

Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med (2001) 6.23

Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med (1999) 6.21

Abdominal adiposity and coronary heart disease in women. JAMA (1998) 6.21

Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med (1999) 6.17